May 29, 2025

Physical Disease Clusters Predict Future Depression Risk

A large UK study found that people with multiple physical health conditions face a significantly higher risk of developing depression, with risk levels varying by type and number of conditions.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 27, 2025

Vagus Nerve Stimulation Shows Knee Pain Relief

A 60-minute session of transcutaneous vagus nerve stimulation reduced knee osteoarthritis pain and improved heart rate variability.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 19, 2025

Growth Disrupted in One-Third of JIA Patients, Study

In a study of 107 children with juvenile idiopathic arthritis, researchers found that one-third had growth or pubertal disturbances—often linked to disrupted hormone levels and longer disease duration.

Conexiant

April 21, 2025

Lupus Clusters Show Distinct Disease Patterns

Cluster 2 patients exhibited ‘a more severe form of the disease, marked with frequent serositis and haematological manifestations, renal and neurological involvement,’ and had poorer outcomes over time.

Conexiant

April 30, 2025

New AI Sensor Diagnoses Osteoarthritis and Rheumatoid Arthritis

A new AI-assisted gold sensor distinguished osteoarthritis from rheumatoid arthritis with 98.1% accuracy by analyzing synovial fluid, offering a fast, noninvasive diagnostic option, researchers report.

Conexiant

April 18, 2025

Gout Remission Linked to Lower Urate, Fewer Flares

Remission in gout after urate-lowering therapy was seldom after 1 but high after 5 years, finds a five-year NOR-Gout study tracking 211 patients.

Conexiant

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant